Welcome to our dedicated page for Aeon Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AEON Biopharma SEC filings document its ABP-450 biosimilar program, operating and financial results, governance matters, capital structure, and NYSE American listing-status disclosures. Form 8-K reports cover material events such as financial results, Regulation FD presentations, executive appointments and compensatory arrangements, and continued-listing rule notices tied to stockholders’ equity requirements.
Proxy statements record shareholder voting procedures and meeting proposals, including capital-structure approvals tied to Class A common stock, warrants, and senior secured convertible note matters. The filings also identify AEON’s Class A common stock listed on NYSE American and describe disclosure topics common to a development-stage biopharmaceutical issuer.
AEON Biopharma, Inc. furnished a new corporate investor presentation on its website and via an exhibit to a current report. The presentation, dated May 2026 and labeled as Exhibit 99.1, may be used by management in future meetings to discuss the company.
The company states that the presentation includes a slide titled “Forward-Looking Statements” for important cautionary information. AEON also clarifies that the materials furnished under Item 7.01, including Exhibit 99.1, are not deemed filed under the securities laws and are not automatically incorporated into other SEC filings.
AEON Biopharma, Inc. reported a net loss of $11.8 million for the three months ended March 31 2026, compared with net income of $9.1 million a year earlier. Operating expenses rose as selling, general and administrative costs reached $3.9 million and research and development expenses were $2.0 million.
Results were heavily influenced by fair value movements on financing instruments, including an $8.7 million loss on convertible notes and a $4.7 million gain on warrants. AEON ended the quarter with cash and cash equivalents of $6.2 million and total liabilities of $25.4 million, resulting in a stockholders’ deficit of $16.8 million.
The company raised equity through its at-the-market program, issuing 1,278,776 shares for net proceeds of about $1.7 million, and completed a $6.0 million PIPE financing spanning late 2025 and early 2026. It also exchanged $15.0 million of Daewoong-held convertible notes into equity, a new $1.5 million note and 8.0 million warrants at $1.09392/share.
Management disclosed recurring losses, a significant accumulated deficit of $482.6 million, limited cash and dependence on additional financing, concluding there is substantial doubt about AEON’s ability to continue as a going concern. The company continues developing its ABP‑450 botulinum toxin biosimilar program and plans to advance analytical and regulatory interactions with the FDA during 2026.
AEON Biopharma reported first-quarter 2026 results and a corporate update focused on its ABP-450 biosimilar program and balance sheet. The company recorded a net loss of $11.8 million for the quarter, compared with net income of $9.1 million in the prior-year period, largely driven by fair value changes in financial instruments.
Operating expenses rose as selling, general and administrative costs reached $3.9 million and research and development spending was $2.0 million. AEON ended March 31, 2026 with cash and cash equivalents of $6.2 million, and stated that, including $0.9 million of April ATM proceeds, this is expected to fund operations into the third quarter of 2026.
The company highlighted positive FDA feedback from a BPD Type 2a meeting supporting ABP-450’s analytical similarity strategy under the 351(k) biosimilar pathway. AEON also completed a $6 million PIPE financing and a Daewoong note exchange, which together reduced outstanding debt by more than 90% and contributed to shrinking total stockholders’ deficit from $(55.0) million to $(16.8) million.
AEON Biopharma, Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 17, 2026 at 10:00 a.m. Pacific Time at its Irvine, California offices. Holders of Class A Common Stock at the close of business on April 21, 2026, when 26,307,211 shares were outstanding, may vote in person or by proxy.
Stockholders are being asked to elect Class III directors Marc Forth and Seongsoo Park to terms running to the 2029 annual meeting, and to ratify KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy statement also details board structure, committee assignments, governance policies, and 2025 compensation for key executives, including new CEO Robert Bancroft, Chief Medical Officer Chad Oh, and Chief Legal Officer Alex Wilson.
Bencich John reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma, Inc. reported that Chief Financial Officer John Bencich received a grant of 754,717 shares of Class A common stock in the form of restricted stock units. The award was granted on April 1, 2026 and carries no purchase price per share.
The restricted stock units vest in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date, contingent on continued service through each vesting date. Following this award, Bencich is shown as directly owning 754,717 shares of Class A common stock.
Bencich John reported acquisition or exercise transactions in this Form 4 filing.
AEON Biopharma, Inc. reported that Chief Financial Officer John Bencich received a grant of 754,717 shares of Class A common stock in the form of restricted stock units. The award was granted on April 1, 2026 and carries no purchase price per share.
The restricted stock units vest in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date, contingent on continued service through each vesting date. Following this award, Bencich is shown as directly owning 754,717 shares of Class A common stock.
AEON Biopharma, Inc. filed an initial insider ownership report for its Chief Financial Officer, John Bencich. This filing is a Form 3, which serves as the starting disclosure of his beneficial ownership in AEON as an officer. The report does not list any specific transactions or share movements.
AEON Biopharma, Inc. filed an initial insider ownership report for its Chief Financial Officer, John Bencich. This filing is a Form 3, which serves as the starting disclosure of his beneficial ownership in AEON as an officer. The report does not list any specific transactions or share movements.
AEON Biopharma, Inc. reported that NYSE American sent an additional notice stating the company no longer meets an extra continued listing standard. The exchange requires stockholders’ equity of at least $4.0 million when a company has losses in three of its four most recent fiscal years.
AEON instead reported a stockholders’ deficit of approximately $55 million as of December 31, 2025, along with losses in three of its four most recent fiscal years. The company is already operating under a previously accepted plan to regain compliance by August 3, 2026.
The new notice does not immediately affect trading of AEON’s Class A common stock, which will continue to list on NYSE American with a “.BC” below‑compliance indicator and inclusion on the noncompliant issuers list. If AEON fails to regain compliance by August 3, 2026, NYSE American may begin delisting proceedings, which AEON would have the right to appeal.
AEON Biopharma, Inc. reported that NYSE American sent an additional notice stating the company no longer meets an extra continued listing standard. The exchange requires stockholders’ equity of at least $4.0 million when a company has losses in three of its four most recent fiscal years.
AEON instead reported a stockholders’ deficit of approximately $55 million as of December 31, 2025, along with losses in three of its four most recent fiscal years. The company is already operating under a previously accepted plan to regain compliance by August 3, 2026.
The new notice does not immediately affect trading of AEON’s Class A common stock, which will continue to list on NYSE American with a “.BC” below‑compliance indicator and inclusion on the noncompliant issuers list. If AEON fails to regain compliance by August 3, 2026, NYSE American may begin delisting proceedings, which AEON would have the right to appeal.
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing ABP-450 as a biosimilar to Botox for all approved therapeutic indications in the U.S. under the FDA’s Section 351(k) pathway. The company holds exclusive therapeutic rights to ABP-450 across the U.S., Canada, the EU, the U.K. and certain other territories and is targeting the roughly $3.3 billion U.S. therapeutic botulinum toxin market, which is projected to grow about 8% annually and is dominated by Botox.
ABP-450 is the same 900 kDa botulinum toxin complex marketed cosmetically as Jeuveau/Nuceiva and is manufactured by Daewoong in cGMP-inspected facilities. AEON is pursuing an “analytical-first” biosimilar strategy, has held multiple FDA biosimilar program (BPD) meetings, and plans to complete most analytical comparability work in 2026 before moving to the next phase of development.
The company emphasizes potential full-label clinical substitutability with Botox and a differentiated, therapy-only BLA structure that could support distinct reimbursement economics in buy-and-bill settings. However, AEON has never been profitable and reported an accumulated deficit of $470.8 million as of December 31, 2025. Management concludes there is substantial doubt about AEON’s ability to continue as a going concern without additional financing, expecting its current cash (including $4.2 million from a January 2026 closing) to fund operations only into the third quarter of 2026.
AEON Biopharma reported a sharp swing to loss for 2025 while advancing its ABP-450 biosimilar program and repairing its balance sheet. For the year ended December 31, 2025, net loss was $39,222 thousand, compared with net income of $42,005 thousand in 2024, driven largely by volatile fair value and warrant-related items.
Total operating costs and expenses were $12,803 thousand, versus $(72,985) thousand in 2024, when a large non-cash reduction in contingent consideration had boosted results. AEON ended 2025 with cash and cash equivalents of $3,006 thousand, total liabilities of $60,587 thousand, and a stockholders’ deficit of $55,027 thousand, highlighting a highly leveraged capital structure.
Strategically, the company reported positive initial analytical biosimilarity data for ABP-450 versus BOTOX, a favorable FDA BPD Type 2a meeting outlining a clear analytical path, and a $6 million PIPE financing and Daewoong note exchange that reduced outstanding debt by more than 90%.